Clinical efficacy and mechanism of polyene phosphatidylcholine combined with atorvastatin in treating metabolic associated fatty liver disease.

BACKGROUND

Metabolic associated fatty liver disease (MAFLD) is mainly caused by liver cell steatosis or fat storage due to lipid metabolism disorders. It may induce the diseases such as liver cirrhosis and liver cancer.

OBJECTIVES

Our study aimed to explore the efficacy and mechanism of polyene phosphatidylcholine (PPC) combined with atorvastatin (ATV) in treating MAFLD.

METHODS

Ninety-two MAFLD patients were divided into control and observation groups which received PPC alone and PPC combined with ATV for six months. The total therapeutic efficiency, liver function indicators, blood lipid indicators, inflammatory factors and liver injury indexes were evaluated and compared between two groups.

RESULTS

After treatment, comparing to the control group, in the observation group the total effective rate was significantly increased and the liver function indicators, blood lipid indicators, inflammatory factors and liver injury index transforming growth factor-β (TGF-β) and nuclear transcription factor-κB (NF-κB) levels were significantly improved (all P < 0.05).

CONCLUSION

PPC combined with ATV is superior to PPC alone in improving the liver function, lipid metabolism, inflammation and liver injury without increasing the adverse reactions. It may represent a safe adjunct strategy in MAFLD management.